Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547169 · ClinicalTrials.gov registry record · Phase 2
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01547169 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 60 participants.
The verdict
NCT01547169, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The study will examine the effects of intranasally administered long-acting insulin detemir on cognition in persons with Alzheimer's disease (AD) or amnestic mild cognitive impairment (aMCI). The rationale for these studies is derived from growing evidence that insulin contributes to multiple brain functions, and that insulin dysregulation can contribute to AD pathogenesis. Thus, therapies aimed at restoring normal insulin signaling in the CNS may have beneficial effects on brain function. Intranasal administration of insulin increases insulin signaling in brain without raising peripheral levels and causing hypoglycemia. Insulin detemir is an insulin analogue that may have better action in brain than other insulin formulations because of its albumin binding properties. The investigators will test the therapeutic effects of intranasally-administered insulin detemir in a dose-finding study in which participants will receive one of two doses of insulin detemir or placebo for a three week period. The investigators will test the hypothesis that either dose will improve memory and daily functioning in persons with AD/aMCI compared with placebo.
Interventions
- DRUG Placebo Comparator
- DRUG insulin detemir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01547169
The ClinicalTrials.gov registry entry for NCT01547169 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT01547169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01547169 about?
NCT01547169 is a clinical study titled "Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days". The study will examine the effects of intranasally administered long-acting insulin detemir on cognition in persons with Alzheimer's disease (AD) or amnestic mild cognitive impairment (aMCI). The rationale for these studies is derived from growing evidence that insulin contributes to multiple brain ...
What is the current status of trial NCT01547169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2011-03. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01547169?
The interventions under investigation include: Placebo Comparator (DRUG), insulin detemir (DRUG).
Who is sponsoring clinical trial NCT01547169?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.